Eli Lilly and Co. has agreed to buy Verve Therapeutics Inc. for up to $1.3 billion, in a move that bolsters Lilly’s push into gene editing for cardiovascular conditions and signals renewed confidence in the sector. The all-cash tender offer values Verve at $10.50 per share upfront. That’s a 113% premium over the company’s 30-day…